Spherico's Asembia 2023 Takeaways

Asembia’s annual Access to Pharmacy Summit draws thousands of the nation's leading pharmacy and pharmaceutical industry decision-makers to Las Vegas each year for three days of continued education, business development, and networking.

We sat down with our Spherico, a division of GSW, attendees: SVP, Market Access Strategy Sara Rubin and SVP, Group Account Director Leana Katz, to discuss their takeaways and trends that the market access industry should know about. Check out their insights below.

Throughout the 20+ sessions, what topics did you see covered the most?

"IDN engagement, patient support solutions, and payer trends were covered throughout the conference. I had the opportunity to sit on Syneos Health's IDN engagement panel, where we discussed the critical success factors of engaging IDNs, from initial customer segmentation to the omnichannel execution that these IDNs are expecting." - Sara Rubin, SVP, Market Access Strategy, Spherico, a division of GSW

"The Inflation Reduction Act was a hot topic throughout Asembia, with many sessions covering how this complex legislation affects the different aspects of our industry." - Leana Katz, SVP, Group Account Director, Spherico, a division of GSW

What upcoming trends should the market access industry be aware of?

"Patient support programs are becoming an industry norm, but they are only impactful if companies execute them correctly. These programs have a tremendous opportunity to fill gaps and unmet needs, but the patient experience and ease of accessibility need to be the platform's main focus." - Sara Rubin, SVP, Market Access Strategy, Spherico, a division of GSW

"The total number of launches in 2023 is down compared to 2022, and it's becoming more and more difficult to launch a successful drug. As the frequency of high-cost treatment launches accelerates, pressure is being put on the rest of the market to contain cost. Companies now need to prepare for an 18-36 month investment window." - Leana Katz, SVP, Group Account Director, Spherico, a division of GSW

What are your overall takeaways?

"We're always finding the best ways to support IDN customers, payers, and patients, but that involves deep research and segmentation. For IDNs in particular, many are closed and/or short-staffed, so consider omnichannel and digital execution in your engagement plan." - Sara Rubin, SVP, Market Access Strategy, Spherico, a division of GSW

"There are more innovative therapies coming to market than ever before, and it's an exciting time in the pharmaceutical industry. But, because of expanded payer control and longer launch windows, companies must not only consider access barriers when forming their launch strategy but also engage their market access agency earlier in the process." - Leana Katz, SVP, Group Account Director, Spherico, a division of GSW

If you're interested in connecting with our market access experts, reach out to Melissa Bojorquez at [email protected] to start the conversation.